Boothbay Fund Management’s Summit Therapeutics SMMT Stock Holding History

Boothbay Fund Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-53,964	Closed	-$1.02M	–	2600
2026 Q1	$1.02M	Buy	+53,964	New	+$873K	0.01%	936
2025 Q2	–	Sell	-50,000	Closed	-$965K	–	1741
2025 Q1	$965K	Buy	+50,000	New	+$1M	0.03%	645
2024 Q2	–	Sell	-35,000	Closed	-$145K	–	1831
2024 Q1	$145K	Buy	35,000 +5,000	+17%	+$19.9K	﹤0.01%	1378
2023 Q4	$78.3K	Hold	30,000	–	–	﹤0.01%	1460
2023 Q3	$56.1K	Hold	30,000	–	–	﹤0.01%	1623
2023 Q2	$75.3K	Sell	30,000 -126,995	-81%	-$232K	﹤0.01%	1645
2023 Q1	$275K	Sell	156,995 -64,210	-29%	-$175K	0.01%	1562
2022 Q4	$940K	Buy	+221,205	New	+$402K	0.02%	924
2022 Q3	–	Sell	-81,559	Closed	-$82K	–	2572
2022 Q2	$82K	Sell	81,559 -73,391	-47%	-$103K	﹤0.01%	2016
2022 Q1	$380K	Buy	+154,950	New	+$391K	0.01%	1464

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Boothbay Fund Management's SMMT Position: Q2 2026 in Review

Boothbay Fund Management sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 53,964 shares — an estimated $1.02M sold.

Boothbay Fund Management first reported a position in SMMT in Q1 2022 and held it in 10 quarters. The position peaked at $1.02M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Boothbay Fund Management reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 53,964 Summit Therapeutics shares in Q2 2026, an estimated $1.02M.
Boothbay Fund Management first reported a position in Summit Therapeutics in Q1 2022 and held it in 10 quarters.
Boothbay Fund Management's Summit Therapeutics position peaked at $1.02M in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.